Ireland declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The Ledger in 2024
Page 9 of 11 of this archive, newest first.
Ireland declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
South Africa caps semaglutide prescribing to 8 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
SURPASS-3 was built to answer the stopping question, and it did
What was withdrawn, from whom, after how long, and what was measured afterwards.
Ireland caps liraglutide prescribing to 22 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Why a result on one vial says less than the trade needs it to
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
Saudi Arabia declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Sweden caps dulaglutide prescribing to 22 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Sweden caps dulaglutide prescribing to 7 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Sweden declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Ireland declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
South Korea caps tirzepatide prescribing to 21 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Sweden declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
How a claim degrades between the bench and the listing
Lot-level verification with a public report is a real and achievable thing. It exists in this market, on a minority of listings.
The submitted sample: the weakest link in the whole system
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
Germany caps tirzepatide prescribing to 9 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
France declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The shortage years, and what they taught about interruption
A supply interruption is a discontinuation with no notice, no taper and no plan. That is a distinct clinical situation.
Ireland caps tirzepatide prescribing to 21 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The United Kingdom declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.